Expression profiling of CD4+and CD8+ T cells in peripheral blood (PB) of AML patients who were treated with induction chemotherapy plus pomalidomide

Transcriptional profiles of highly purified (≥ 98%) PB CD4+ or CD8+ T cells at early lymphocyte recovery (ELR) from newly diagnosed AML patients, who were treated with standard induction chemotherapy plus pomalidomide were compared to age-matched AML controls, who received standard induction chemotherapy only. AML patients treated with induction chemotherapy + Pomalidomide (CP) vs. AML patients treated with induction chemotherapy only (C)